Erratum: Shibata S.; et al. Proton Beam Therapy without Fiducial Markers Using Four-Dimensional CT Planning for Large Hepatocellular Carcinomas. Cancers 2018, 10, 71
Autor: | Kazutaka Yamamoto, Mariko Kawamura, Satoko Asahi, Satoshi Kobayashi, Yuji Tameshige, Miu Mizuhata, Hiroyasu Tamamura, Yoshitaka Sato, Makoto Sasaki, Yoshikazu Maeda, Tomoyasu Kumano, Sayuri Bou, Shigeyuki Takamatsu, Satoshi Shibata, Toshifumi Gabata |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Physics Cancer Research Proton Four-Dimensional CT business.industry hepatocellular carcinoma lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens respiratory-gated irradiation lcsh:RC254-282 Article proton beam therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine n/a Oncology 4-dimensional CT planning 030220 oncology & carcinogenesis Fiducial marker Nuclear medicine business Beam (structure) |
Zdroj: | Cancers, Vol 10, Iss 12, p 508 (2018) Cancers |
ISSN: | 2072-6694 |
Popis: | We evaluated the effectiveness and toxicity of proton beam therapy (PBT) for hepatocellular carcinomas (HCC) >5 cm without fiducial markers using four-dimensional CT (4D-CT) planning. The subjects were 29 patients treated at our hospital between March 2011 and March 2015. The median total dose was 76 Cobalt Gray Equivalents (CGE) in 20 fractions (range; 66–80.5 CGE in 10–32 fractions). Therapy was delivered with end-expiratory phase gating. An internal target volume (ITV) margin was added through the analysis of respiratory movement with 4D-CT. Patient age ranged from 38 to 87 years (median, 71 years). Twenty-four patients were Child–Pugh class A and five patients were class B. Tumor size ranged from 5.0 to 13.9 cm (median, 6.9 cm). The follow-up period ranged from 2 to 72 months (median; 27 months). All patients completed PBT according to the treatment protocol without grade 4 (CTCAE v4.03 (draft v5.0)) or higher adverse effects. The two-year local tumor control (LTC), progression-free survival (PFS), and overall survival (OS) rates were 95%, 22%, and 61%, respectively. The LTC was not inferior to that of previous reports using fiducial markers. Respiratory-gated PBT with 4D-CT planning without fiducial markers is a less invasive and equally effective treatment for large HCCs as PBT with fiducial markers. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |